JBIO

Jade Biosciences, Inc.

Price Chart

Latest Quote

$20.86

+0.38 (+1.86%)

Current Price

Previous Close	$20.48
Open	$19.88
Day High	$21.45
Day Low	$19.40
Volume	637,760

Fetched: 2026-07-18T04:26:08

Stock Information

Shares Outstanding	60.86M
Total Debt	$808K
Cash Equivalents	$311.30M
Net Income	$-95.10M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$1.27B
EPS (TTM)	$-2.68
Exchange	NCM

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$719.16M
Income	$-95.10M
Book/sh	$6.01
Cash/sh	$5.11
Employees	55

Financial Ratios

Quick Ratio	13.96
Current Ratio	14.29
Debt/Eq	0.27

Returns & Margins

Ownership

Insider Ownership	0.83%
Institutional Ownership	88.14%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-9.15
P/B	3.47

Analyst Data

Recommendation	none
Target Price	$48.50

Technical Indicators

SMA20	$21.36
SMA50	$20.74
SMA200	$15.97
RSI	41.39
ATR	1.7332

Shares Float	39.69M
Short Float	16.55%
Short Ratio	4.89
Rel Volume	0.48

Performance History

Week	-0.43%
Month	+34.32%
Quarter	-4.66%
6 Months	+42.29%
YTD	+47.32%
Year	+136.78%
3 Years	-96.67%
5 Years	-95.93%
10 Years	-97.32%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-07-17	$20.86	659,500
2026-07-16	$20.48	1,285,000
2026-07-15	$21.86	803,900
2026-07-14	$21.34	1,217,900
2026-07-13	$21.30	1,587,700
2026-07-10	$20.95	1,413,200
2026-07-09	$22.48	646,400
2026-07-08	$22.53	878,500
2026-07-07	$22.45	1,042,400
2026-07-06	$21.30	1,056,300
2026-07-02	$21.51	1,204,500
2026-07-01	$21.81	861,600
2026-06-30	$22.22	893,400
2026-06-29	$22.11	1,122,600
2026-06-26	$22.00	2,664,300
2026-06-25	$21.81	826,400
2026-06-24	$21.90	1,397,100
2026-06-23	$21.97	1,410,100
2026-06-22	$19.45	1,869,800
2026-06-18	$16.82	4,785,300

About Jade Biosciences, Inc.

Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.

📰 Latest News

Is Jade Biosciences, Inc. (JBIO) Stock a Rising Biotech Opportunity in the $20B IgA Nephropathy Market?

Insider Monkey • 2026-06-30T13:21:13Z

Jade Biosciences’ JADE101 Delivers Deep IgA Cuts, Clearing Path for Kidney Trials

MarketBeat • 2026-06-02T01:07:58Z

Assessing Jade Biosciences (JBIO) Valuation After Recent Share Price Weakness And Longer Term Gains

Simply Wall St. • 2026-05-29T01:03:44Z

Companies Like Jade Biosciences (NASDAQ:JBIO) Are In A Position To Invest In Growth

Simply Wall St. • 2026-03-28T12:14:17Z

Jade Biosciences Touts “Best-in-Class” Autoimmune Antibodies, JADE101 Phase 1 Readout Nears

MarketBeat • 2026-02-28T16:41:34Z

H.C. Wainwright Initiates Jade Biosciences (JBIO) at Buy With $25 PT as JADE101 Eyes $926M Peak Revenue

Insider Monkey • 2026-01-19T13:01:49Z

Institutional investors in Jade Biosciences, Inc. (NASDAQ:JBIO) must be dismayed after prices dropped by 16% last week

Simply Wall St. • 2026-01-06T12:07:13Z

Jade Biosciences (JBIO): Analyst Lauds Entry into Market

Insider Monkey • 2025-12-10T19:15:52Z

Does Jade Biosciences, Inc. (JBIO) Have the Potential to Rally 65% as Wall Street Analysts Expect?

Zacks • 2025-12-04T14:55:02Z

What Makes Jade Biosciences, Inc. (JBIO) a New Buy Stock

Zacks • 2025-11-18T17:00:04Z

Period:

Income Statement (Annual)

Metric	2025-12-31
Revenue
Total Revenue	$0
Operating Revenue	$0
Expenses
Total Expenses	$113,542,000
Other Income Expense	$-21,592,000
Other Non Operating Income Expenses	$-21,592,000
Net Non Operating Interest Income Expense	$7,782,000
Operating Expense	$113,542,000
General And Administrative Expense	$20,421,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-127,410,000
Net Interest Income	$7,782,000
Interest Income	$7,782,000
Normalized Income	$-127,410,000
Net Income From Continuing And Discontinued Operation	$-127,410,000
Total Operating Income As Reported	$-113,542,000
Net Income Common Stockholders	$-127,410,000
Net Income	$-127,410,000
Net Income Including Noncontrolling Interests	$-127,410,000
Net Income Continuous Operations	$-127,410,000
Pretax Income	$-127,352,000
Interest Income Non Operating	$7,782,000
Operating Income	$-113,542,000
Per Share
Diluted EPS	$-3.19
Basic EPS	$-3.19
Other
Tax Effect Of Unusual Items	$0
Tax Rate For Calcs	$0
Normalized EBITDA (Bullshit earnings)	$-113,516,000
Reconciled Depreciation	$26,000
EBITDA (Bullshit earnings)	$-113,516,000
EBIT	$-113,542,000
Diluted Average Shares	$31,359,958
Basic Average Shares	$31,359,958
Diluted NI Availto Com Stockholders	$-127,410,000
Tax Provision	$58,000
Research And Development	$93,121,000
Selling General And Administration	$20,421,000
Other Gand A	$7,730,000
Salaries And Wages	$12,691,000

Fetched: 2026-07-15

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31
Assets
Net Tangible Assets	$332,518,000	$-46,799,000
Total Assets	$349,781,000	$72,799,000
Total Non Current Assets	$965,000	$3,145,000
Other Non Current Assets	$69,000	$3,145,000
Current Assets	$348,816,000	$69,654,000
Other Current Assets	$12,658,000	$268,000
Cash Cash Equivalents And Short Term Investments	$336,158,000	$69,386,000
Cash And Cash Equivalents	$88,438,000	$69,386,000
Debt
Total Debt	$724,000	$107,600,000
Long Term Debt And Capital Lease Obligation	$724,000	$107,600,000
Net Debt	-	$38,214,000
Long Term Debt	-	$107,600,000
Liabilities
Total Liabilities Net Minority Interest	$17,263,000	$119,598,000
Total Non Current Liabilities Net Minority Interest	$724,000	$107,602,000
Current Liabilities	$16,539,000	$11,996,000
Payables And Accrued Expenses	$13,216,000	$8,128,000
Payables	$2,151,000	$1,290,000
Accounts Payable	$2,151,000	$1,290,000
Other Current Liabilities	-	$1,077,000
Equity
Common Stock Equity	$332,516,000	$-46,799,000
Preferred Stock Equity	$2,000	-
Total Equity Gross Minority Interest	$332,518,000	$-46,799,000
Stockholders Equity	$332,518,000	$-46,799,000
Gains Losses Not Affecting Retained Earnings	$129,000	$0
Other Equity Adjustments	$129,000	-
Retained Earnings	$-174,389,000	$-46,979,000
Preferred Securities Outside Stock Equity	$0	$2,000
Other
Ordinary Shares Number	$49,316,287	$32,235,926
Share Issued	$49,316,287	$32,235,926
Tangible Book Value	$332,516,000	$-46,799,000
Invested Capital	$332,516,000	$60,801,000
Working Capital	$332,277,000	$57,658,000
Capital Lease Obligations	$724,000	$0
Total Capitalization	$332,518,000	$60,801,000
Additional Paid In Capital	$506,771,000	$179,000
Capital Stock	$7,000	$1,000
Common Stock	$5,000	$1,000
Preferred Stock	$2,000	$0
Long Term Capital Lease Obligation	$724,000	$0
Pensionand Other Post Retirement Benefit Plans Current	$3,323,000	$2,791,000
Current Accrued Expenses	$11,065,000	$6,838,000
Net PPE	$896,000	$0
Gross PPE	$896,000	$0
Other Properties	$896,000	-
Other Short Term Investments	$247,720,000	$0

Fetched: 2026-07-15

Cash Flow Statement (Annual)

Metric	2025-12-31
Free Cash Flow
Free Cash Flow	$-94,885,000
Operating Activities
Operating Cash Flow	$-94,689,000
Cash Flow From Continuing Operating Activities	$-94,689,000
Investing Activities
Capital Expenditure	$-196,000
Investing Cash Flow	$-247,006,000
Cash Flow From Continuing Investing Activities	$-247,006,000
Net Other Investing Changes	$-31,000
Financing Activities
Issuance Of Capital Stock	$189,111,000
Financing Cash Flow	$360,768,000
Cash Flow From Continuing Financing Activities	$360,768,000
Net Other Financing Charges	$171,273,000
Net Common Stock Issuance	$189,111,000
Common Stock Issuance	$189,111,000
Other
Issuance Of Debt	$0
End Cash Position	$88,438,000
Beginning Cash Position	$69,386,000
Effect Of Exchange Rate Changes	$-21,000
Changes In Cash	$19,073,000
Proceeds From Stock Option Exercised	$384,000
Net Issuance Payments Of Debt	$0
Net Long Term Debt Issuance	$0
Long Term Debt Issuance	$0
Net Investment Purchase And Sale	$-246,779,000
Sale Of Investment	$14,415,000
Purchase Of Investment	$-261,194,000
Net PPE Purchase And Sale	$-196,000
Purchase Of PPE	$-196,000
Change In Working Capital	$-8,197,000
Change In Other Current Liabilities	$40,000
Change In Other Current Assets	$-38,000
Change In Payables And Accrued Expense	$3,770,000
Change In Accrued Expense	$3,409,000
Change In Payable	$361,000
Change In Account Payable	$361,000
Change In Prepaid Assets	$-11,969,000
Other Non Cash Items	$21,667,000
Stock Based Compensation	$20,009,000
Amortization Of Securities	$-784,000
Depreciation Amortization Depletion	$26,000
Depreciation And Amortization	$26,000
Depreciation	$26,000
Net Income From Continuing Operations	$-127,410,000

Fetched: 2026-07-15